Making life science life changing
We help promising scientific ideas reach the next phase of development through investment, partnerships and expertise for health conditions that need it most.
Scientific expertise
30 years of experience in antibody humanisation, diagnostics and biomarker development, and drug development.
Funding and investment
See our open funding calls or learn more about how we invest in early-stage ventures.
Intellectual property and tech transfer
Help with licensing and collaborative development, at a lower risk to you.
Interested in partnering with us?
We can work together to connect you with the right support for your project.
Our Translational Challenges
Motor Neuron Disease
Our vision is a world where motor neuron disease is preventable and treatable.
Chronic Respiratory Infection
Our vision is improved quality of life for those living with cystic fibrosis and bronchiectasis.
Global Health
Our vision is a world with affordable and accessible solutions to better understand, treat, and prevent infectious diseases.
Rare Disease
Our vision is an ecosystem working together to get discoveries and treatments to rare disease patients faster.
Childhood Cancer
Our vision is to drive life-changing innovations for children with cancer.
What’s happening at LifeArc
Our work in neurodegeneration
We’re working to improve prediction and diagnosis of neurodegenerative conditions.
2023 annual review
Read about the projects and initiatives that made 2023 at LifeArc such an eventful and successful year.
We’re hiring!
We’re looking for talented people to join the LifeArc team.
Chronic respiratory infection drug repurposing call
We are committing £3 million to support drug repurposing projects that seek to conduct translational studies.
MND drug repurposing call
A new £5 million programme to help find new treatments for motor neuron disease.
Latest news
-
Third global Longitude Prize to be launched in 2025 focusing on ALS
-
LifeArc appoints Chief Medical Officer to deliver more scientific breakthroughs for patients
-
£2.7m infectious disease fund to boost rapid testing, drug trials and innovative specimen storage